Description de l'entreprise
Illumina is improving human health by unlocking the power of the genome. The company's focus on innovation has established us as the global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical and applied markets. Illumina's products are used for applications in the life sciences, oncology, reproductive health, agriculture and other emerging segments.
Conseil d'administration & Conseil de surveillance
| PDG |
| Jacob Thaysen, PhD |
| Conseil d'administration |
| Ankur Dhingra, Steve Barnard, PhD, Nicole Berry, Todd Christian, Everett Cunningham, Scott Davies, Pat Leckman, Kevin Pegels, Carissa Rollins, Salli Schwartz, Bas Verhoef, Jakob Wedel, Gretchen Weightman, Jenny Zheng |
| Conseil de surveillance |
| Stephen P. MacMillan, Jacob Thaysen, PhD, Frances Arnold, PhD, Caroline Dorsa, Robert S. Epstein, Scott Gottlieb, Gary S. Guthart, Anna Richo, Philip Schiller, Sue Siegel, Scott B. Ullem |
Données de l'entreprise
| Nom: |
Illumina Inc. |
| Adresse: |
5200 Illumina Way,San Diego, California 92122, USA |
| Téléphone: |
+1-858-202-4500 |
| Fax: |
+1-858-202-4766 |
| Courriel: |
info@illumina.com
|
| Internet: |
www.illumina.com/ |
| Industrie: |
Healthcare |
| Secteur: |
Medical Products |
| Sous-secteur: |
Advanced Medical Devices |
| Fin de l'exercice financier: |
31/12 |
| Flotte libre: |
48.29% |
| IPO date: |
28/07/2000 |
Relations avec les investisseurs
| Nom: |
- |
| Téléphone IR: |
+1-858-291-6421 |
| IR-Fax: |
- |
| E-mail IR: |
ir@illumina.com
|
